Find in Library

Background: Allergic rhinitis (AR) is an inflammatory immune disorder that occurs due to IgE-mediated hypersensitivity. Morin, a plant flavonoid exhibits inhibitory potential against IgE-mediated allergic diseases. Aim: To evaluate the efficacy and possible mechanism of action of morin against ovalbumin (OVA)-induced AR in BALB/c mice. Materials and methods: AR was induced in mice by OVA (500 μl, i.p.) and challenged (5 μl per nostril) on the 21st day. Mice were treated with morin (10, 30 and 100 mg/kg, p.o.) for 21 days. Results: OVA-challenge caused significant (p < 0.05) induction of nasal symptoms (rubbing, sneezing, and discharge) whereas administration of morin (30 and 100 mg/kg) significantly (p < 0.05) attenuated it as compared to AR control mice. The OVA-induced elevated levels of serum histamine, IgE, IgG1, β-hexosaminidase, nasal lavage fluid Th2 cytokines (IL-4, IL-5, IL-13, and IL-17), and decreased levels of nasal lavage fluid Th1 cytokines (IFN-γ) were significantly (p < 0.05) attenuated by morin. RT-PCR and western blot analysis revealed that morin treatment significantly (p < 0.05) down-regulated splenic mRNA and protein expressions of GATA3, p-STAT6, and SOCS1, significantly up-regulated (p < 0.05) T-bet expression as compared to AR control mice. OVA-induced alterations in nasal mucosa and spleen were significantly ameliorated (p < 0.05) by morin treatment. Conclusion: The findings of presented investigation demonstrated that morin exerts its anti-allergic effect against OVA-induced allergic rhinitis via inhibition of p-STAT6 that down-regulates expression of SOCS1 and GATA3/T-bet pathway which modulates the release of Th1/Th2 cytokines and IgE levels thus, inhibiting allergen-induced hypersensitivity.